Treatment optimization for recurrent hepatoblastoma: retrospective study from a hepatoblastoma cohort in Southern China
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Apr 2022 · 1 min read
In brief
In brief
Retrospective analysis of 42 recurrent hepatoblastoma cases in Southern China identifies surgical resection or ablation as optimal treatment strategies. Patients with curable recurrent disease achieved similar progression-free survival outcomes as primary hepatoblastoma cases when treated with surgery or ablation, while chemotherapy regimen changes correlated with poorer outcomes.
Written by the GCMD Library team from the article.
Abstract
Purpose
The present study aimed to explore the clinical characteristics and optimal treatments of RHB patients.
Methods
We retrospectively collected 42 RHB cases and 161 primary HB (PHB) cases. Clinical characteristics were compared between RHB and PHB patients. The risk factors related to overall survival (OS) and progression-free survival (PFS) in RHB patients were explored by COX regression analysis. Patients were further divided into curable and refractory subgroup by treatments. Propensity score match (PSM) analysis was performed to match recurrent curable patients from 145 curable PHB patients from the same cohort. PFS was further compared between 34 pairs of primary and recurrent curative HB patients.
Results
Recurrence treatment and number of relapsed tumors were significantly related with both OS and PFS of RHB patients (p < 0.05). Chemotherapy regimen alteration was also risk factor of PFS for RHB (HR = 4.26; 95% CI = 1.54–11.78; p = 0.005). RHB patients underwent curable treatment had better prognosis, compared with recurrent refractory subgroup (p < 0.001). Matched curable PHB patients demonstrated no significant difference of 3-year PFS with curable RHB patients (p = 0.540).
Conclusion
Curable RHB patients might get benefit from surgery or ablation with similar prognosis with primary curable HB patients.